Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa
Preclinical research led by scientists from the University of Pennsylvania demonstrates effective delivery and expression of functional gene sequences, positive effects on retinal structure and function, and improved visual navigation in animal models
View HTML
Toggle Summary AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Appoints William Sullivan as Chief Financial Officer, Andrew Ashe Named General Counsel
Seasoned executives bring extensive operating and financial experience
View HTML
Toggle Summary IND-Enabling Study Data Published in Human Gene Therapy Clinical Development Support Clinical Development of AGTC-402 for the Treatment of CNGA3-deficient Achromatopsia
Preclinical study demonstrates that AGTC-402 significantly improved vision in a large animal model of achromatopsia
View HTML
Toggle Summary AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study
GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced topline
View HTML
Toggle Summary Data Published in Molecular Therapy Demonstrate Five-Year Response Following a Single Dose of an Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency
Clinical study led by researchers at the University of Massachusetts Medical School demonstrates sustained protein expression and improvements in multiple indicators of AAT biological activity
View HTML
Toggle Summary AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting
Results support AGTC's clinical development strategies in both conditions Phase 1/2 trial in patients with achromatopsia due to CNGB3 mutations is currently enrolling patients; Phase 1/2 trial in patients with CNGA3-related achromatopsia is scheduling patients for enrollment WASHINGTON, May 11,
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Results expected to enhance development of AGTC's XLRS gene therapy candidate; Phase 1/2 clinical trial currently enrolling patients at multiple locations across the United States
View HTML
Toggle Summary AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 10, 2017
GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it
View HTML
Visionary science for life changing cures.